SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData, Phase II drugs for Lymphoblastic Lymphoma have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SENL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hebei Senlang Biotechnology overview
Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.
For a complete picture of SENL-101’s drug-specific PTSR and LoA scores, buy the report here.